m6A modified circQSOX1 can recruit miR-326 and miR-330-5p to increase the expression of PGAM1, enhance the glycolysis of CRC, increase the production of lactate, promote the immune escape of CRC and reduce the therapeutic effect of anti-CTLA-4. Here, CTLA4 is linked to colorectal carcinoma.